Aptimmune

Aptimmune

Aptimmune

Aptimmune Biologics specializes in the development and application of prophylactic measures against viral diseases of swine.
Type
B2b
Raised
$8.4M
Follow us
Alexa global traffic share
Latest funding
$6,000,000
Venture capital (Series B) - 2018
Cultivation Capital The Yield Lab St. Louis Arch Angels +2
$2,420,000
Venture capital (Series A) - 2016
Arsenal Capital Partners Fox Ventures
Team Size
1–10
Employees

No recent coverage

Index constantly checks hot and trending companies for their latest activity. We haven't gotten to this company yet, but if you follow it you'll be the the first to know when Aptimmune makes some noise.